novo glp-1 Novo's Wegovy becomes first drug approved for MASH Novo Holdings Bolsters GLP-1 Production

The FDA notes the most severe adverse events include melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and prolonged and painful boners

Hypertension is an independent predisposing factor for heart failure, coronary artery disease, stroke, retinopathy, nephropathy, and peripheral arterial diseases (Sawicka et al., 2011

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight with weight-related conditions

However, this feature is also exploited by cancer cells to acquire drug resistance and improve their survival